Inside Precision Medicine March 29, 2024
A clinical trial led by investigators at The Keck Medicine of USC will investigate the feasibility of providing immunotherapy treatment at home for patients with non-small cell lung cancer (NSCLC).
Currently, immunotherapies are only administered intravenously in a doctor’s office or hospital. But the new trial will examine the effectiveness of a new formulation atezolizumab, an approved immunotherapy for particular types of NSCLC, to see if it can be safely and effectively administered subcutaneously by a nurse in a patient’s home. The regimen will also include telemedicine appointments and remote monitoring of patients via wearable trackers.
“Many types of drugs are now being delivered subcutaneously at home for several conditions, and we hypothesize that this method of drug delivery can...
Today's Sponsors
Today's Sponsor